Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas. The company will engage in a fireside chat on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT).
The company's senior management team will be available for one-on-one meetings during the conference. Interested parties can arrange meetings through their Jones representative or by contacting Yuki Gonzalez, Vice President of Marketing & Corporate Access.
A recording of the fireside chat will be made available on Theravance.com under the Investors section, Events and Presentations, and will remain accessible for 30 days following the event.
Details
News Market Reaction – TBPH
The recorded move for TBPH in the trading session of this news was -3.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. To attend the fireside chat and schedule meetings with management, please contact your Jones representative or email Yuki Gonzalez, Vice President, Marketing & Corporate Access (ygonzalez@jonestrading.com).
A recording of the event will be available after the conference and may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. The recording will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302415277.html
SOURCE Theravance Biopharma, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.